Norovirus Antiviral Candidate Enters Key Trial
Adults who face norovirus, which has no approved drug, may one day have an oral treatment option, though results are not expected until 2026 or 2027.
Updated on Nov. 4, 2026 in COVID-19

Live Poll
Do you trust that new norovirus treatments will be developed in the coming years?
Cocrystal Pharma's CDI-988, an oral antiviral candidate, is in a placebo-controlled phase 1b human challenge study at Emory University School of Medicine for norovirus, a virus with no specific approved treatment. The same period brought a setback for Moderna, whose norovirus vaccine candidate mRNA-1403 did not meet early success criteria at a phase 3 interim analysis.
Why it matters
Norovirus causes roughly 900 deaths and 109,000 hospitalizations a year in the U.S., and no medication currently treats it, so people with the illness rely on supportive care. Cocrystal is pursuing a narrower strain-specific strategy, and the Moderna setback shows how difficult broad norovirus prevention has been.
CDI-988 is being tested in a placebo-controlled phase 1b human challenge study at Emory University School of Medicine, which has completed dosing its last participant. Results are not yet available, so no efficacy figures can be reported at this stage.
The players
Cocrystal Pharma
A biopharmaceutical company developing CDI-988, an oral antiviral candidate for norovirus treatment and prophylaxis.
Moderna
A biotechnology company known for its mRNA platform, whose norovirus vaccine candidate mRNA-1403 is in phase 3 testing.
Emory University School of Medicine
A medical school hosting the placebo-controlled phase 1b human challenge study of CDI-988.
Centers for Disease Control and Prevention
The U.S. federal public health agency that publishes national estimates of norovirus deaths and hospitalizations.
The details
CDI-988 is an oral antiviral designed to target norovirus. Cocrystal is taking a different approach from earlier efforts by focusing its challenge study on one specific norovirus strain rather than the full range of strains. Other companies that pursued broad coverage across strains were not successful, so Cocrystal plans to pursue the remaining strains only if the strain-specific approach works.
Timeline
July 2026: Moderna reported that mRNA-1403 did not meet early success criteria at its phase 3 interim analysis.
Late 2026 or early 2027: Cocrystal expects preliminary results from the CDI-988 study.
Health Landscape
Norovirus has no approved medication, and vaccine efforts such as Moderna's mRNA-1403 have not yet met early success criteria in phase 3 interim analysis. CDI-988's FDA fast track designation places an antiviral candidate among the few pipeline efforts aiming to give the condition its first targeted drug option.
Norovirus is a common cause of vomiting and diarrhea, and the CDC's burden estimates show it can be serious enough to require hospital care. Because no medication treats it now, people with severe symptoms should talk to their doctor about hydration and supportive care, and this research is still years from becoming a practical option.
The takeaway
Norovirus remains a major cause of illness and hospitalization with no approved drug, so new antiviral research is worth following. Prevention through frequent handwashing and staying home when sick remains the practical step to discuss with your healthcare provider.
What happens next
Cocrystal expects preliminary results from the CDI-988 phase 1b study in late 2026 or early 2027, and says it will pursue other norovirus strains if the strain-specific study shows promise.
Further reading
For broader context on respiratory and viral disease research, explore our COVID-19 coverage.
Source note: This article includes information reported by Labroots.
Live Poll
Do you trust that new norovirus treatments will be developed in the coming years?





